Full Press Release Details
of Paul Brennan as Non-Executive Director
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated
pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect
Mr Brennan has extensive experience in the health
system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer
(CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from a market capitalisation of $30M to a high
of $2B. Prior to this Mr Brennan was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew
Healthcare for 6 years.
Commenting on his appointment, Paul Brennan said,
"Immuron has unique intellectual property that places it at the forefront of gut health. This emerging field of medical advancement,
coupled with Immuron's strength in clinical research, should deliver significant market opportunity. I am looking forward to working
closely with the team."
Dr. Roger Aston, Non-Executive
Chairman, said, "we are delighted with the appointment of Paul to the Board as he brings a diverse background including commercialisation
of technology, company governance, strategic planning and international marketing and more."
This release has been authorised by the directors
Dr Jerry Kanellos, Ph.D.
Ph: +61 (0)3 9824 5254
Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of infectious diseases.
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a
digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly
purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed
medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product
(NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement
for digestive tract protection.
About Travelers' diarrhea
Travelers' diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating and fever. Enteropathogenic
bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter
spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery
organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers' diarrhea
as they may be contracted while travelling and initial symptoms are often indistinguishable.
For more information
visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.